**ABSTRACT**

Dyskeratosis congenita (DC) is a clinically and genetically heterogeneous, multisystem inherited syndrome with a very high risk for bone marrow failure (BMF) and cancer predisposition. The classical clinical form of DC is characterized by abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. Bone marrow failure is considered to be an important and major complication of DC and the leading cause of death which develops in around 85% of cases. A number of genes involved in telomere maintenance are associated with DC, such as genes that encode the components of the telomerase complex (TERT, DKC1, TERC, NOP10, and NHP2), T-loop assembly protein (RTEL1), telomere capping (CTC1), telomere shelterin complex (TINF2), and telomerase trafficking protein (TCAB1). Mutations in TINF2 have been reported in 11–20% of all patients with DC and have been associated with bone marrow failure. Here we report on a 19-month-old boy with very early presentation of bone marrow failure as a first clinical manifestation of DC. Upon first admission, the patient presented with thrombocytopenia and macrocytic anemia. Soon after, his blood counts deteriorated with the development of pancytopenia and aplastic anemia. Four months later, he developed nail dystrophy and skin hyperpigmentation. A de novo heterozygous pathogenic variant c.845G>A, p.(Arg282His) was located in exon 6 of TINF2 gene and was identified via clinical exome sequencing. The findings confirmed the diagnosis of DC. This is the first case with DC due to TINF2 pathogenic variant reported in North Macedonia.

**Keywords**

TINF2 gene mutation; Aplastic anemia; DC

**INTRODUCTION**

Dyskeratosis congenita (DC) is a clinically and genetically heterogeneous multisystem inherited syndrome caused by mutations in genes that encode the protein components of the telomerase complex and shelterin complex. DC is a rare disease with an estimated annual incidence of 1 in 1,000,000 [1]. Genotype–phenotype correlations are complex due to a variety of gene mutations, disease anticipation, and genetic and environmental modifier effects. The classical clinical form of the disease is characterized by the mucocutaneous triad of abnormal skin pigmentation, nail dystrophy, and leukoplakia [2, 3]. The abnormal skin pigmentation and nail changes usually appear first, often under 10 years of age. Additional features of the clinical presentation include BMF, myelodysplastic syndrome (MDS), epiphora, blepharitis, premature graying, alopecia, growth retardation, cerebellar hypoplasia and microcephaly, esophageal stenosis, urethral stenosis, liver disease, pulmonary fibrosis, and avascular necrosis of the hips or shoulders. DC patients have an increased risk of developing malignant disease [4, 5]. Bone marrow failure is considered to be an important and major complication of DC, and is a leading cause of death that develops in around 85% of cases. DC is caused by mutations in genes that encode protein components of the telomerase complex and shelterin complex. Since 1998 at least 14 DC genes involved in the telomere’s shortening have been identified, accounting for approximately 70–80% of DC cases [6-8]. These genes encode proteins for the
TINF2 GENE MUTATION ASSOCIATE WITH APLASTIC ANEMIA IN DC

maintenance of telomeres, which are located at the ends of chromosomes. DC can be inherited in an X-linked, autosomal dominant (AD), or autosomal recessive (AR) pattern. Mutations in TINF2 have been reported in 11–20% of all patients with DC and have been associated with bone marrow failure [9]. In addition, mutations of TINF2 were also identified in patients with other diseases associated with bone marrow failure (e.g. ataxia-pancytopenia and aplastic anemia) [10, 11]. In this paper we report on a 19-month old boy with de novo heterozygous mutation in the TINF2 gene and a very early presentation of bone marrow failure as a first clinical manifestation of DC.

CASE PRESENTATION

A 19-month-old boy was referred to the hematology department at the University clinic for children’s diseases in order to evaluate the possibility of thrombocytopenia. He is of Albanian ancestry, born after a normal pregnancy from healthy parents. There is no consanguinity in the family. Clinical examination at admission revealed pallor, cutaneous and mucosal hemorrhagic syndrome. He had growth retardation below the third percentile on the growth curve. Laboratory tests have shown thrombocytopenia (with PLT 27 x 10^9/l), with macrocytic anemia (Hb: 102 g/L, RBC 3.3 x 10^12/l, MCV: 98.2 fL) and WBC: 6.03 x 10^9/l, neutrophil count of 1.25 10^9/l. BM analysis showed megaloblastic maturation in BM with megakaryocyte hypoplasia. Chromosome analysis indicated no numerical or structural chromosomal abnormalities. The following month, the PLT number decreased to 7 x 10^9/l with the development of severe macrocytic anemia (Hb 72g/L; RBC 2.3 x10^12/l). Blood counts deteriorated with the development of pancytopenia and aplastic anemia. Four months later, a physical examination revealed nail dystrophy and skin pigmentation involving the neck. Differential diagnosis suggested Fanconi anemia or DC. The diagnosis of DC was established with the identification of a known pathogenic de novo TINF2 gene mutation. The clinical characteristic and hematologic findings during the follow up are summarized in Table 1.

GENETIC ANALYSIS AND RESULTS

We performed clinical exome sequencing on a MiSeq desktop sequencer, using TruSight One kit (Illumina) for the proband. The analysis revealed the presence of the known pathogenic variant c.845G>A, p.(Arg282His), in a heterozygous state, in the TINF2 gene (Figure 1). Amplification and Sanger sequencing of TINF2 exon 6 showed the absence of the variant in the proband’s parents. DNA analysis using the AmpFLSTR Identifiler PCR Amplification Kit confirmed the biological relationship between the child and his parents. Thus, the TINF2 c.845G>A variant has arisen as a de novo event in the proband. Schematic representation of the pathogenic TINF2 gene variants is presented in Figure 2.
Table 1. Hematology results and clinical characteristic during the follow up

| Analysis                              | 1st admission | 2 months | 4 months |
|---------------------------------------|---------------|----------|----------|
| Hb (g/l)                              | 102           | 86       | 72       |
| RBC (10^6/l)                          | 3.3           | 2.6      | 2.3      |
| MCV (fl)                              | 98.2          | 102      | 105      |
| WBC (10^3/l)                          | 6.03          | 4.8      | 4.9      |
| Granulocyte (10^9/l)                  | 1.25          | 1.0      | 0.8      |
| PLT (10^9/l)                          | 27            | 12       | 7        |
| BM aspiration and BM biopsy           |               |          |          |
| Nail dystrophy                        | No            | No       | Present  |
| Skin hyperpigmentation                | No            | No       | Present  |
| Mucosal Leucoplaikia                  | No            | No       | No       |
| Genetic analyses                      |               |          |          |

TREATMENT

The medical management of each DC patient is very complex and should take into consideration the patient’s specific needs. Patients with DC and BMF do not respond to immunosuppressive therapy, and allogeneic hematopoietic stem cell transplantation (HSCT) is the only curative treatment for BMF. Our patient received corticosteroids for one month without any response to the therapy. After the confirmation of DC, HSCT was performed by an unrelated full matched donor. The patient experienced engraftment failure and underwent a second unrelated HSCT. One year after the second HSCT he was in a good clinical condition. Once the bone marrow failure issue was resolved, thrombocytes were around 30-40 x 10^9/l and the boy had a relatively good quality of life.

DISCUSSION

We report the clinical, laboratory and genetic findings of a 19-month-old Albanian boy from North Macedonia with aplastic anemia as a first clinical presentation of DC. A known pathogenic missense variant, c.845G>A, p.(Arg282His), located in exon 6 of the TINF2 gene, was identified as responsible for DC in our patient. Autosomal dominant DC is a clinically and genetically heterogeneous group of the disease. To date, heterozygous variants in 4 genes (TERC, TERT, RTEL1 and TINF2) have been characterized. Patients harboring TINF2 variants are reported to have extremely short telomeres, and a frequent early age of presentation (less than 10 years old), and they often present severe manifestation of the disease [8, 14]. Nearly all patients have de novo TINF2 variants that give rise to a different mechanism that causes the disease. List of the known TINF2 pathogenic variants reported to date is given in Table 2. TINF2 mutations can be associated with a broad spectrum of phenotypes (Table 2, on the next page). The classical clinical form of the disease is characterized by dysplastic nails, lacy reticular pigmentation of the upper chest and/or neck and oral leukoplakia. BMF, myelodysplastic syndrome (MDS), epiphora, blepharitis, premature graying, alopecia, growth retardation, cerebellar hypoplasia and microcephaly, esophageal stenosis, urethral stenosis, liver disease, pulmonary fibrosis, and avascular necrosis of the hips or shoulders can be included in the clinical presentation. Progressive bone marrow failure may appear at any age and may be the only sign until the age of 10. Macrocytosis and elevated hemoglobin F levels may be seen in these patients. Patients have an increased risk of the development of malignant disease. Solid tumors may be the first manifestation of DC in persons who do not have BMF and are younger than 50 years of age [15]. Most DC patients have normal intelligence and development of motor skills. In severe forms of the disease, developmental delay may occur. In Hoyeraal Hreidarsson syndrome, a severe form of the disease, affected individuals have an unusually small and underdeveloped cerebellum and intrauterine growth retardation. In addition to the other symptoms of dyskeratosis congenita, bilateral exudative retinopathy and intracranial calcifications are characteristic for the other severe variant of DC, called Revesz syndrome [16]. Pulmonary fibrosis was found in DC patients with the c.844C>T p.(Arg282Cys), c.851C>G p.(Thr284Arg) and c.872_875del p.(Arg291IlefsTer25) TINF2 pathogenic variants [14, 17, 18].

The TINF2 pathogenic variant c.845G>A, p.Arg282His that was identified in our patient has been previously reported in patients with severe clinical presentations, such as Hoyeraal Hreidarsson syndrome and Revesz syndrome (8, 11).

CONCLUSION

DC is a rare genetic disorder with genetic and clinical heterogeneity. Patients with aplastic anemia should be screened for this rare condition, even when they do not have a classical clinical form. Reporting different cases increases our knowledge of the disease and its heterogeneity. Early diagnosis allows for prevention of severe invasive infections and non-infectious complications, thus improving the success of transplantation and overall prognosis of DC.

Declaration of Interest. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.
TINF2 GENE MUTATION ASSOCIATE WITH APLASTIC ANEMIA IN DC

REFERENCES

1. Walne AJ, Marrone A, Dokal I: Dyskeratosis congenita: a disorder of defective telomere maintenance? Int J Hematol 2005; 82:184–189.

2. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000; 110: 768-779.

3. Bessler M, Wilson DB, Mason PJ. Dyskeratosis congenita. FEBS Lett. 2010; 584: 3831-3838.

4. Ballew BJ, Savage SA. Updates on the biology and management of dyskeratosis congenita and related telomere biology disorders. Expert Rev Hematol. 2013; 6: 327–37.

5. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita. Blood. 2009; 113(26): 6549-57.

6. Heiss NS, Knight SW, Vulliamy T, SM Klauck, SWiemann, P J Mason et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved

Table 2. List of known pathogenic TINF2 gene variants

| Chr Position (GRCh37) | Nucleotide change (NM_001099274) | Amino acid change (NP_001092744) | rs ID | Phenotype | Publication (Reference) |
|-----------------------|----------------------------------|----------------------------------|------|-----------|------------------------|
| chr14:24711458        | c.81C>A                           | p.Cys27Ter                        | rs1060499576 | DC, RS     | /                      |
| chr14:24709890        | c.796C>T                           | p.Arg266Ter                       | rs1064795632 | N/A       | /                      |
| chr14:24709881        | c.805C>T                           | p.Gln269Ter                       | rs387907153 | DC, mucocutaneous features, BMF | 19, 18 |
| chr14:24709875        | c.811C>T                           | p.Gln271Ter                       | rs387907154 | AA        | 19                     |
| chr14:24709860        | c.826delA                          | p.Arg276GlyfsTer41                | rs863223324 | ND, BMF, lichenoid tongue, dry skin, intrauterine growth retardation | 18 |
| chr14:24709848        | c.838A>T                           | p.Lys280Ter                       | rs121918543 | DC, HHS, and RS | 12, 15 |
| chr14:24709848        | c.838A>G                           | p.Lys280Glu                       | rs121918543 | DC         | 12, 21, 8              |
| chr14:24709847        | c.839delA                          | p.Lys280ArgfsTer37               | rs1594551449 | DC, RS    | 19                     |
| chr14:24709842        | c.844C>A                           | p.Arg282Ser                       | rs121918545 | DC, RS     | 12, 17, 23             |
| chr14:24709842        | c.844C>T                           | p.Arg282Cys                       | rs121918545 | DC, AA, PD and mucosal changes | 20, 12, 17 |
| chr14:24709841        | c.845G>A                           | p.Arg282His                       | rs121918544 | DC, HHS, RS | 12, 22, 17, 24, 25, 26, 27, 28 |
| chr14:24709839        | c.847C>T                           | p.Pro283Ser                       | rs199422311 | DC, HHS    | 12, 15                 |
| chr14:24709839        | c.847C>G                           | p.Pro283Ala                       | rs199422311 | DC         | 12, 15                 |
| chr14:24709838        | c.848C>A                           | p.Pro283His                       | rs199422313 | DC         | 12, 15                 |
| chr14:24709837        | c.849delC                          | p.Thr284GlnfsTer33               | /       | ND, BMF    | 18                     |
| chr14:24709837        | c.849_850insC                      | p.Thr284HisfsTer8                | rs199422315 | DC, AA     | 12, 15                 |
| chr14:24709836        | c.850A>G                           | p.Thr284Ala                       | rs199422314 | DC         | 12, 15                 |
| chr14:24709835        | c.851C>A                           | p.Thr284Lys                       | /       | DC         | 18                     |
| chr14:24709835        | c.851C>G                           | p.Thr284Arg                       | /       | BMF, hair loss, dental loss, PD, short stature, osteoporosis | 18 |
| chr14:24709829        | c.857delTinsGC                     | p.Met286SerfsTer5                | /       | ND, BMF, microcephaly, low immunoglobulins | 18 |
| chr14:24709826        | c.860T>C                           | p.Leu287Pro                       | rs199422316 | DC         | 12, 15                 |
| chr14:24709824        | c.862T>C                           | p.Phe288Leu                       | rs199422317 | DC         | 12, 15                 |
| chr14:24709821        | c.865C>T                           | p.Pro289Ser                       | rs1555304055 | N/A       | 29                     |
| chr14:24709820        | c.865_866delinsAG                  | p.Pro289Ser                       | rs199422318 | DC         | 12, 15                 |
| chr14:24709819        | c.867_868insC                      | p.Phe290L.eufsTer2               | /       | DC         | 12                     |
| chr14:24709815        | c.871A>G                           | p.Arg291Gly                       | rs199422319 | DC         | 12, 15                 |
| chr14:24709812        | c.872_875del                       | p.Arg291HesfsTer25               | /       | DC, PD     | 14                     |
| chr14:24709794        | c.892delC                          | p.Gln298ArgfsTer19               | rs199422320 | DC         | 12, 15                 |
| chr14:24709508        | c.1090dup                          | p.Leu364ProfsTer9                | rs1566366182 | DC         | /                      |

DC - Dyskeratosis congenita, HHS - Hoyeraal Hreidarsson syndrome, RS - Revesz syndrome, BMF - Bone marrow failure, AA - Aplastic anemia, PD - Pulmonary disease, ND - Nail dystrophy
gene with putative nucleolar functions. Nat Genet. 1998; 19: 32-38.

7. Walne AJ, Dokal I: Advances in the understanding of dyskeratosis congenita. Br J Haematol. 2009; 145: 164-172.

8. Savage SA, Giri N, Baerlocher GM, Orr N, Lansdorp PM, Alter BP: TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet. 2008; 82: 501-509.

9. Calado RT (ed): Progress in Molecular Biology and Translational Science, ed 1. Waltham, Academic Press, 2014.

10. Du HY, Mason PJ, Bessler M, and Wilson DB. Pediatr. Blood Cancer. 2009; 52: 687.

11. Tsangaris E, Adams SL, Yoon G, Chitayat D, Lansdorp P, Dokal I, and Dror Y. Hum. Genet. 2008; 124: 507-513.

12. Walne AJ, Vulliamy T, Beswick R, Michael K, Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood. 2008; 112(9): 3594–3600.

13. Sarper N, Zengin E, Kilic SC. A child with severe form of dyskeratosis congenita and TINF2 mutation of shelterin complex. Pediatr Blood Cancer. 2010; 55(6):1185–1186.

14. Fukuhara A, Tanino Y, Ishii T, Inokoshi Y, Saito K, Fukuhara N et al. Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation. Eur Respir J. 2013; 42: 1757–1759.

15. Savage SA. Dyskeratosis Congenita. 2009 Nov 12 [updated 2019 Nov 21]. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mirzaa G, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from http://www.ncbi.nlm.nih.gov/books/NBK22301/ Citation on PubMed

16. Karremann M, Neumaier-Probst E, Schlichtenbrede F, Beier F, Brümmedorf TH, et al. Revesz syndrome revisited. Orphanet J Rare Dis. 2020; 15: 299.

17. Hongchun D, Yubiao G, Di M, Kejing T, Decheng C, et al. A case report of heterozygous TINF2 gene mutation associated with pulmonary fibrosis in a patient with dyskeratosis congenita. Medicine (Baltimore). 2018; 97(19): e0724.

18. Vulliamy T, Beswick R, Kirwan MJ, Hossain U, Walne AJ, and Dokal I. Telomere length measurement can distinguish pathogenic from non-pathogenic variants in the shelterin component, TINF2. Clin Genet. 2012; 81(1): 76-81.

19. Sasa GS, Ribes-Zamora A, Nelson ND, Bertuch AA. Three novel truncating TINF2 mutations causing severe dyskeratosis congenita in early childhood. Clin Genet. 2012; 81(5): 470-8.

20. Gutierrez-Rodrigues F, Donaires FS, Pinto A, Vicente A, Dillon LW et al. Pathogenic TERT promoter variants in telomere diseases. Genet Med. 2019; 21(7): 1594-1602.

21. Yang D, He Q, Kim H, Ma W, Songyang Z. TINF2 protein dyskeratosis congenita missense mutants are defective in association with telomerase. J Biol Chem. 2011; 286 (26): 23022-30.

22. Li F, Li W, Qiao X, Xie X. Clinical features of dyskeratosis congenita in mainland China: case reports and literature review. Int J Hematol. 2019; 109(3): 328-335.

23. Pereboeva L, Hubbard M, Goldman FD, Westin ER. Robust DNA Damage Response and Elevated Reactive Oxygen Species in TINF2-Mutated Dyskeratosis Congenita Cells. PLoS One. 2016; 11(2): e0148793.

24. Nelson ND, Dodson LM, Escudero L, Sukumar AT, Williams CL, Mihaelei I, et al. The C-Terminal Extension Unique to the Long Isoform of the Shelterin Component TIN2 Enhances Its Interaction with TRF2 in a Phosphorylation and Dyskeratosis Congenita Cluster-Dependent Fashion. Mol Cell Biol. 2018; 38(12): e00025-18.

25. Norberg A, Rosén A, Raaschou-Jensen K, Kjeldsen L, Moilanen JS, Paulsson-Karlsson Y, et al. Novel variants in Nordic patients referred for genetic testing of telomere-related disorders. Eur J Hum Genet. 2018; 26(6): 858-867.

26. Mouska K, Huang JN, Moore AT. Revesz syndrome masquerading as traumatic retinal detachment. J AAPOS. 2017; 21(5): 422-425.

27. Monoi A, Sugawa M, Kato M, Seki M, Yoshida K, Shiraishi Y, et al. Atypical dyskeratosis congenita diagnosed using whole-exome sequencing. Pediatr Int. 2017; 59(8): 933-935.

28. Guidugli L, Johnson AK, Alkorta-Aranburu G, Arndt T, Decheng C, et al. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia. 2017; 31(5): 1226-1229.

29. Tomcikova D, Gerince A, Busanov B, Gresikova M, Biskup S, Kortnagel K. Why is it necessary to examine retina when the patient suffers from aplastic anemia? Bratisl Lek Listy. 2018;119(5): 275-277.